This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effectiveness of amiodarone as primary or secondary prevention in sudden cardiac death (SCD) compared with placebo or any other antiarrythmics in patients with high risk for sudden cardiac death, or who have recovered from a cardiac arrest or a syncope due to VT/VF. We aim to conduct a subgroup analysis for patients with or without ICD.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.